Oryzon Genomics S.A.

About Oryzon Genomics S.A.

Company Description

Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds Vafidemstat and Iadademstat in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States.

Year founded

2000

Served area

Europe + North America

Headcount

Headquarters

Carrera de San Jeronimo 15, 28014 Madrid – Spain

Publications

Filing	Q1 Results	H1 Results	9M Results	FY Results
Report				ESP

Filing	Q1 Results	H1 Results	9M Results	FY Results
Report				ESP

Filing	Q1 Results	H1 Results	9M Results	FY Results
Report				ESP

Filing	Q1 Results	H1 Results	9M Results	FY Results
Report				ESP

Filing	Q1 Results	H1 Results	9M Results	FY Results
Report				ESP

Filing	Q1 Results	H1 Results	9M Results	FY Results
Report				ESP

Filing	Q1 Results	H1 Results	9M Results	FY Results
Report				ESP

Filing	Q1 Results	H1 Results	9M Results	FY Results
Report				ESP

Contact

Email address

First name

Last name

Phone number

Company

Your message

Yes, I have read, understand and agree to the Privacy Policy

About Oryzon Genomics S.A.

Publications

Shareholder information

Contact

Newsletter